---
title: "Long-term Metformin Randomization Linked to Lower Dementia Risk and Better Memory in Diabetes Prev"
id: "medrxiv-15-randomized-metformin-and-cognitive-outcomes-in-the-diabetes-prevention-program"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-15-randomized-metformin-and-cognitive-outcomes-in-the-diabetes-prevention-program"
content_type: "clinical_feed_article"
specialty: "Endocrinology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.05.26359234v1?rss=1"
published_at: "2026-08-07T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Long-term Metformin Randomization Linked to Lower Dementia Risk and Better Memory in Diabetes Prev
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-15-randomized-metformin-and-cognitive-outcomes-in-the-diabetes-prevention-program
- **Specialty:** [Endocrinology](https://medichelpline.com/clinical-feed/endocrinology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.05.26359234v1?rss=1)
- **Published At:** 2026-08-07T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This randomized follow-up study evaluated whether allocation to **metformin** versus placebo or intensive lifestyle intervention (ILS) in the Diabetes Prevention Program (DPP) affected later cognitive outcomes during the Diabetes Prevention Program Outcomes Study (DPPOS). - Participants were adults at high risk for type 2 diabetes enrolled across 27 U.S. centers; follow-up included adjudication of cognitive impairment syndromes and repeated cognitive testing between 2009 and 2024. - Total mean metformin exposure in the originally randomized metformin arm was 15.5 ± 7.7 years/person; participants in the placebo and ILS arms received shorter out-of-study metformin exposure (means 4.5 ± 5.1 and 3.8 ± 4.8 years/person, respectively), typically after diabetes onset. - Cognitive syndromes were adjudicated in 1,483 participants (median age 74, IQR 68–80) using the National Alzheimer’s Coordinating Center Uniform Dataset v3 during 2022–2024. - Randomization to metformin was associated with lower odds of dementia compared with placebo (OR 0.40, 95% CI 0.17–0.97) and compared with ILS (OR 0.38, 95% CI 0.16–0.89) after adjustment for demographics, education, income, and APOE-ε4 genotype. - Randomization to metformin was also associated with significantly better longitudinal **memory** performance (β = 0.58; 95% CI 0.09–1.1; p = 0.02; Cohen’s d = 0.1). - Overall distributions of cognitive syndromes did not differ significantly by treatment group, and estimates were noted to be imprecise due to a limited number of dementia cases. - Authors conclude that long-term metformin exposure is associated with reduced dementia risk and better memory among persons with prediabetes or type 2 diabetes, but emphasize need for longer follow-up and more dementia events to confirm findings. - The report is a preprint that has not been peer reviewed and includes competing interest disclosures and trial registrations for DPP and DPPOS.
## Clinical Analysis & Structured Key Points
Randomized metformin and cognitive outcomes in the Diabetes Prevention Program Outcomes Study | medRxiv Skip to main content Randomized metformin and cognitive outcomes in the Diabetes Prevention Program Outcomes Study View ORCID Profile Pandora L Wander , View ORCID Profile Lindsay Doherty , View ORCID Profile Qing Pan , View ORCID Profile Owen Carmichael , View ORCID Profile Raymond Turner , View ORCID Profile Shihchen Kuo , View ORCID Profile Medha Munshi , View ORCID Profile Amisha Wallia , View ORCID Profile James Noble , View ORCID Profile Vallabh O Shah , View ORCID Profile Neelesh K Nadkarni , View ORCID Profile Sunder Mudaliar , View ORCID Profile Dana Dabelea , View ORCID Profile Marinella Temprosa , View ORCID Profile William C Knowler , View ORCID Profile David M Nathan , View ORCID Profile Jose A Luchsinger , DPP Research Group doi: https://doi.org/10.64898/2026.08.05.26359234 Pandora L Wander 1 Veterans Affairs (VA) Puget Sound Health Care System and Department of Medicine, University of Washington; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Pandora L Wander Lindsay Doherty 2 Biostatistics Center and Department of Biostatistics and Bioinformatics, George Washington University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Lindsay Doherty Qing Pan 2 Biostatistics Center and Department of Biostatistics and Bioinformatics, George Washington University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Qing Pan Owen Carmichael 3 Biomedical Imaging Center, Pennington Biomedical Research Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Owen Carmichael Raymond Turner 4 Department of Neurology, MedStar Georgetown University Hospital and Georgetown University Medical Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Raymond Turner Shihchen Kuo 5 Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, Medical School, University of Michigan; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Shihchen Kuo Medha Munshi 6 Joslin Diabetes Center, Beth Israel Deaconess Medical Center, Harvard Medical School; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Medha Munshi Amisha Wallia 7 Division of Endocrinology, Metabolism and Molecular Medicine, Department of Medicine, Northwestern University Feinberg School of Medicine; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Amisha Wallia James Noble 8 Department of Neurology, Taub Institute for Research on Alzheimers Disease and the Aging Brain, and the GH Sergievsky Center, Columbia University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for James Noble Vallabh O Shah 9 School of Medicine, Int Medicine, University of New Mexico HSC; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Vallabh O Shah Neelesh K Nadkarni 10 Department of Medicine, Division of Geriatric Medicine and Gerontology, and Department of Neurology, University of Pittsburgh School of Medicine; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Neelesh K Nadkarni Sunder Mudaliar 11 Diabetes/Metabolism Section, VA San Diego HealthCare System; Clinical Professor of Medicine, University of California at San Diego; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Sunder Mudaliar Dana Dabelea 12 Departments of Epidemiology and Pediatrics, Lifecourse Epidemiology of Adiposity and Diabetes (LEAD) Center, University of Colorado Anschutz Medical Campus; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Dana Dabelea Marinella Temprosa 2 Biostatistics Center and Department of Biostatistics and Bioinformatics, George Washington University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Marinella Temprosa William C Knowler 13 Consultant, Biostatistics Center, George Washington University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for William C Knowler David M Nathan 14 Diabetes Center, Massachusetts General Hospital and Harvard Medical School; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for David M Nathan Jose A Luchsinger 15 Departments of Medicine and Epidemiology, Columbia University Irving Medical Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Jose A Luchsinger For correspondence: jal94{at}columbia.edu 16 - Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Importance. Metformin may influence risk of dementia, with prior conflicting observations of protection or harm. Objective. To determine the association of randomization to metformin vs. placebo or intensive lifestyle intervention (ILS) in the Diabetes Prevention Program (DPP) with cognitive outcomes (cognitive impairment syndromes and trajectories of cognitive test performance) during the DPP Outcomes Study (DPPOS). Design, Setting & Participants. Prospective long-term follow-up of DPP/DPPOS participants at 27 U.S. centers among adults who were at high risk for type 2 diabetes (T2D) at baseline. Exposures. Randomization to metformin, placebo, or ILS (1996-1999) for 3.2 years followed by open-label metformin in the original randomized metformin group until 2021. Main Outcomes & Measures. Cognitive impairment syndromes were adjudicated in 2022-2024 in 1,483 participants (median age 74 [IQR 68, 80]) using the National Alzheimer's Coordinating Center Uniform Dataset version 3. Cognitive performance in executive and memory domains was ascertained with repeated cognitive tests between 2009 and 2024. Multinomial logistic regression and mixed-effects models were fit to examine associations of randomization to metformin with cognitive outcomes. Results. Total metformin exposure (mean ± SD) was 15.5 ±7.7 years/person in the metformin group. Persons in the placebo and ILS groups received out-of-study metformin usually after developing diabetes with mean metformin total exposure of 4.5 ±5.1 and 3.8 ±4.8 years/person in the placebo and ILS groups, respectively. Overall, the frequency distributions of the cognitive syndromes did not differ significantly by treatment group; however, randomization to metformin was associated with a 60% (OR 0.40 [95%CI 0.17, 0.97]) and 62% (OR 0.38 [95%CI 0.16, 0.89]) lower odds of dementia compared with placebo and ILS, respectively, after adjustment for demographics, education, income, and APOE-ε4 genotype. Randomization to metformin was also associated with significantly better memory performance over time ( β =0.58; 95%CI: 0.09, 1.1; p=0.02; Cohen's d=0.1). Conclusions and Relevance. Long-term metformin treatment is associated with a reduced risk of dementia and better memory performance among persons with pre-diabetes or T2D. Estimates were imprecise due to a limited number of dementia cases. Longer follow-up with more dementia cases is needed to confirm our findings. Competing Interest Statement JAL reports grants from the National Institutes of Health (NIH) during the conduct of the study, a stipend Wolters Kluwer Stipend for Editor in Chief of a journal, non-financial support from Merck KGaA (Donation of drug and placebo for an NIH clinical trial), personal fees for consulting from Astra Zeneca, Merck KGaA, and Novo Nordisk for consulting outside the submitted work. RT R. Scott Turner reports research support to from BMS, Cognition Therapeutics, Eisai, and Roche, serving on the Speaker's Bureau for Lilly and Axsome, personal fees as consultant for Eisai and Re:Cognition Health, and serving on an External Data Monitoring Committee for Merck. DD has served as speaker for Boehringer Ingelheim. OC reports grant support from NIH, and Eli Lilly Corp, and a consulting agreement with Clario, Inc. JMN receives personal fees as author and editorial work from Wolters-Kluwer, Oxford University Press, and Springer. MM is a consultant for Abbott and Medtronic and receives research funding from Dexcom. Clinical Trial Diabetes Prevention Program: NCT00004992 ; Diabetes Prevention Program Outcomes Study: NCT00038727 ; Diabetes Prevention Program Outcomes Study AD/ADRD: NCT05704309 Clinical Protocols https://dppos.bsc.gwu.edu/web/dppos/dppos Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The study was conducted according to the guidelines set out in the Declaration of Helsinki and all procedures involving research study participants. Prior to initiating the study protocol, each participant provided written informed consent and each study center obtained approval from its respective institutional review board. The trials are registered at ClinicalTrials.gov (Diabetes Prevention Program: NCT00004992 ; Diabetes Prevention Program Outcomes Study: NCT00038727 ; Diabetes Prevention Program Outcomes Study AD/ADRD: NCT05704309 ) I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability In accordance with the NIH Public Access Policy, we continue to provide all manuscripts to PubMed Central including this manuscript DPP/DPPOS has provided the protocols and lifestyle and medication intervention manuals to the public through its public website (https://www.dppos.org). The DPPOS abides by the NIDDK data sharing policy and implementation guidance as required by the NIH/NIDDK (https://repository.niddk.nih.gov/studies/dppos/) https://repository.niddk.nih.gov/studies/dppos/ Funder Information Declared National Institute on Aging National Institute of Diabetes and Digestive and Kidney Diseases, https://ror.org/00adh9b73 , U01 DK048489 , U01 DK048339 , U01 DK048377 , U01 DK048349 , U01 DK048381 , U01 DK048468 , U01 DK048434 , U01 DK048485 , U01 DK048375 , U01 DK048514 , U01 DK048437 , U01 DK048413 National Institute of Diabetes and Digestive and Kidney Diseases , U01 DK048411 , U01 DK048406 , U01 DK048380 , U01 DK048397 , U01 DK048412 , U01 DK048404 , U01 DK048387 , U01 DK048407 , U01 DK048443 , U01 DK048400 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Back to top Previous Next Posted August 07, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Randomized metformin and cognitive outcomes in the Diabetes Prevention Program Outcomes Study Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Randomized metformin and cognitive outcomes in the Diabetes Prevention Program Outcomes Study Pandora L Wander , Lindsay Doherty , Qing Pan , Owen Carmichael , Raymond Turner , Shihchen Kuo , Medha Munshi , Amisha Wallia , James Noble , Vallabh O Shah , Neelesh K Nadkarni , Sunder Mudaliar , Dana Dabelea , Marinella Temprosa , William C Knowler , David M Nathan , Jose A Luchsinger , DPP Research Group medRxiv 2026.08.05.26359234; doi: https://doi.org/10.64898/2026.08.05.26359234 Share This Article: Copy Citation Tools Randomized metformin and cognitive outcomes in the Diabetes Prevention Program Outcomes Study Pandora L Wander , Lindsay Doherty , Qing Pan , Owen Carmichael , Raymond Turner , Shihchen Kuo , Medha Munshi , Amisha Wallia , James Noble , Vallabh O Shah , Neelesh K Nadkarni , Sunder Mudaliar , Dana Dabelea , Marinella Temprosa , William C Knowler , David M Nathan , Jose A Luchsinger , DPP Research Group medRxiv 2026.08.05.26359234; doi: https://doi.org/10.64898/2026.08.05.26359234 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Area Epidemiology Subject Areas All Articles Addiction Medicine (597) Allergy and Immunology (889) Anesthesia (322) Cardiovascular Medicine (4695) Dentistry and Oral Medicine (466) Dermatology (403) Emergency Medicine (632) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1599) Epidemiology (15673) Forensic Medicine (32) Gastroenterology (1180) Genetic and Genomic Medicine (6894) Geriatric Medicine (720) Health Economics (1036) Health Informatics (4872) Health Policy (1414) Health Systems and Quality Improvement (1704) Hematology (568) HIV/AIDS (1310) Infectious Diseases (except HIV/AIDS) (16163) Intensive Care and Critical Care Medicine (1149) Medical Education (652) Medical Ethics (149) Nephrology (706) Neurology (7057) Nursing (358) Nutrition (1060) Obstetrics and Gynecology (1208) Occupational and Environmental Health (988) Oncology (3515) Ophthalmology (1016) Orthopedics (381) Otolaryngology (434) Pain Medicine (458) Palliative Medicine (135) Pathology (696) Pediatrics (1756) Pharmacology and Therapeutics (725) Primary Care Research (752) Psychiatry and Clinical Psychology (5738) Public and Global Health (9569) Radiology and Imaging (2334) Rehabilitation Medicine and Physical Therapy (1409) Respiratory Medicine (1231) Rheumatology (628) Sexual and Reproductive Health (758) Sports Medicine (568) Surgery (753) Toxicology (105) Transplantation (300) Urology (278)
## Related Clinical Research

- [Antidiabetic regimens and risk of cognitive disorders in type 2 diabetes: large retrospective coho](https://medichelpline.com/clinical-feed/plos-one-23-antidiabetic-medications-and-risk-of-cognitive-disorders-in-type-2-diabetes-a.md)
- [GLP-1 receptor agonists and PMOS: evidence, mechanisms, and who may benefit](https://medichelpline.com/clinical-feed/medical-news-today-0-can-glp-1s-really-help-treat-pmos-experts-answer-3-key-questions.md)
- [Which interventions affect biological aging? Epigenetic study finds diet, exercise, and some drugs](https://medichelpline.com/clinical-feed/medical-news-today-0-what-can-and-can-t-slow-down-aging-new-study-offers-clues.md)
- [Antidiabetic Regimens and Risk of Cognitive Disorders in Type 2 Diabetes: Retrospective Cohort Fin](https://medichelpline.com/clinical-feed/pubmed-42636218.md) (DOI: 10.1371/journal.pone.0356138)
- [Undiagnosed type 2 diabetes presenting as DKA with hypertriglyceridemia-induced acute pancreatitis](https://medichelpline.com/clinical-feed/cmaj-1-undiagnosed-type-2-diabetes-presenting-as-diabetic-ketoacidosis-with.md)

## Navigation
- [← Back to Endocrinology Feed](https://medichelpline.com/clinical-feed/endocrinology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.